

AMENDMENTS TO THE DRAWINGS

The attached Replacement Sheets labeled 3 of 4 and 4 of 4 are provided.

Sheet 3 of 4 shows FIG. 3 and FIG. 4A. FIG. 3 has been amended to correct a typographical error. The reference number 25 on the left of pipe 25 has been changed to 26. Support for this amendment is found in paragraph [0068] of the specification.

Sheet 4 of 4 shows FIG. 4B and FIG. 4C. FIG. 4C has been amended to correct typographical errors. The reference number 4 showing the tube or pipette has been added. The reference number 41 has been changed to 37, the second pinch valve and/or micropump. Support for these changes is found in paragraph [0075].

REMARKS

Summary of Amendments to the Specification

Paragraph [0019] has been amended to correct a typographical error. US587322 (Lattin, et al.) has been changed to US5879322 (Lattin, et al.).

Paragraph [0039] has been amended to correct obvious errors. The phrase “an other mean” has been changed to “another means”. The phrase “avoid negative decrease of the active substance due to accumulation of the solvent” has been changed to “avoid negative decrease of the concentration of active substance due to accumulation of the solvent”. Support for these amendments is found in paragraph [0039] as originally filed which describes the carrying off of solvent e.g. by evaporation into the environment and the effect of such carrying off on the active substance.

Paragraph [0068] has been amended to correct typographical errors. Reference number 15 has been changed to 8. Support for this amendment is found in paragraph [0068] and FIG. 3 as originally filed.

Paragraph [0072] has been amended to correct an obvious error. The phrase “administration reservoir 5” has been changed to “drug reservoir 5”. Support for this amendment is found in paragraph [0072] and FIGS. 4A, B and C as originally filed.

Paragraph [0075] has been amended to correct a typographical error. The sentence “The micro pump 37 either pumps solution into the waste reservoir 13 and/or the valve 36 opens and depleted carrier solution is absorbed into the waste reservoir 13” has been amended to recite “The micro pump 37 either pumps solution into the waste reservoir 13 and/or the valve [[36]] 37 opens and depleted carrier solution is absorbed into the waste reservoir 13.” Support for this amendment is found in paragraph [0075] and FIG. 4C as originally filed.

Summary of Claim Amendments

Claim 1 has been amended. New claims 35-37 are being added.

Claim 1 has been amended to recite “A method for transdermal administration, and “dispensing” and “removing” Support for these amendments is found in claim 1 as originally filed and, for example, in paragraph [0064]. Claim 1 has also been amended by replacing the phrase “such that the level of concentration in the administration reservoir decreases” with “wherein”. Support for this amendment is found throughout the specification, and in particular in paragraph [0028],

Claims 2-9 and 12-16 have been amended to recite “The method”. Claims 10 and 11 have been amended to recite “according to claim 2.” Claims 18-34 have been amended to recite “The device”.

Claim 17 is amended by replacing the term “solved” with “dissolved”, omitting the phrases “suitable to receive the active substance solved in the solvent” and “for adsorption of solvent from the administrative reservoir by evaporation” and replacing solvent removal “means” with solvent removal “element”. The “means” term of “interface means” has been omitted.

Claims 19 and 20 are amended by omitting the “means” term of “interface means”.

Claims 21 and 23-25 are amended by replacing “solvent removal means” with solvent removal element”.

Claim 22 is amended to recite the list is Markush group format.

Claim 29 is amended to recite “dispensing device” in agreement with claim 17.

New claim 35 is being added to provide antecedent basis for the term “control device” claim 31.

Support for new claim 36 is found throughout the specification, for example, in claim 17 as originally filed and in paragraphs [0028], [0034], [0035], [0037], [0039], [0056], [0059], [0062], and [0064]. Support for new claim 37 is found, for example, in paragraphs [0046] and [0050].

Conclusion

The fees for extra claims and any other fees associated with this filing may be

charged to Deposit Account No. 50-1123.

Favorable consideration of all pending claims is respectfully requested. The Examiner is asked to the telephone the undersigned, should the Examiner have any questions or believe such a call would expedite prosecution.

Respectfully submitted,



November 29, 2007

Carol W. Burton, Reg. No. 35,465
Hogan & Hartson LLP
1200 17th Street, Suite 1500
Denver, CO 80202
Telephone: 303.454.2454
Facsimile: 303.899.7333